Guided by this strategic approach, the network aims to collectively tackle current and future challenges more effectively.
The European medicines agencies network strategy to 2028 is available below.
The strategy equips the European medicines regulatory network to respond to change and address challenges such as public health emergencies and threats, including antimicrobial resistance.
It focuses on six areas:
The updated network strategy to 2028 builds on the strategy to 2025.
It places greater emphasis on the competitiveness of the EU in developing and manufacturing medicines, ensuring they are accessible and available to EU citizens while leveraging artificial intelligence.
It also highlights the One Health approach, recognising that the health of humans, animals and the wider environment are closely linked.
EMA and the Heads of Medicines Agencies (HMA) adopted the final strategy in March 2025.
They also published a summary of the public consultation results. This public consultation took place between October and November 2024.
In addition, a reflection paper that informed the draft strategy is also available for reference.
For more information, see:
The European medicines agencies network strategy to 2025 guided the network in continuing to enable the supply of safe and effective medicines.
It took into consideration developments in science, medicine, digital technologies, globalisation and emerging health threats, such as the COVID-19 pandemic:
The strategy outlined six priority focus areas, in line with the European Commission's roadmap for a Pharmaceutical strategy for Europe:
A midterm report published in December 2023 found that the COVID-19 pandemic strengthened the network and brought about transformative change in the European system across key strategic areas:
EMA and the HMA published the strategy in December 2020, following its adoption by the HMA and EMA's Management Board.
It was developed via a two-month public consultation. It received early input from stakeholders such as patient, consumer and healthcare-professional organisations, and from industry, academia and veterinary representatives:
The network strategy for 2016 to 2020 focused on strategic priority areas where the network could make a difference to human and animal health in the EU:
The strategy was built around four key themes:
The strategy built on the roadmap to 2015 and the HMA strategy 2011-15.
The EU medicines agencies strategy to 2020 was open for public consultation between March and June 2015.
For more information, see:
EMA's roadmap to 2015 set out the vision and priorities for the Agency for 2011 to 2015:
The three priority areas outlined in the roadmap were:
For information on how the outlined in the 2015 roadmap was been developed, see:
EMA's roadmap to 2010 set out its vision and priorities for 2006 to 2010.
The three priority areas outlined in the roadmap were: